Rosonabant (INN; E-6776) is a drug acting as a CB₁ receptor antagonist/inverse agonist that was under investigation by Esteve as an appetite suppressant for the treatment of obesity. Development of the drug for clinical use was apparently halted shortly after the related CB₁ antagonist rimonabant was discontinued in November 2008,^[when?] due to the reports of severe psychiatric adverse effects such as anxiety, depression, and suicidal ideation associated with it and with similarly acting agents.